9The ATAC(A rimidex,Tamoxifen A one or in Combination) Trialist's Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer first results of the ATAC randomized trial[J].Lancet,2002,359(9324):2131-2139.
10Goss PE,Ingle JN,Martino S,et al.Randomized placebo-controlled trail of letrozole in postmenopausal women with early breast cancer completing five years of tamoxifen[J].Breast Cancer Res Treat,2003,82(Supple 1):42.
二级参考文献33
1[1]Meakin JW, Hayward JL, Panzarella T, et al. Ovarian irradiation an d prednisone following surgery and radiotherapy for carcinoma of the breast. Bre ast Cancer Res Treat，1996，37:11-18
2[2]Bent Ejlertsen,Per Dombermowsky.Comparable effect ovarian ablation and CMF chemotherapy in Premenopausal hormone receptor positive breast cancer p atient.Proceeding of ASCO,1999,18∶66-70
3[3]Blamey RW, Jonat W, Kaufmann M, et al. Goserelin depot in the trea tment of premenopausal advanced breast cancer. Eur J Cancer， 1992，28A:810-812
4[4]Makris A, Powles TJ, Ashley SE, et al. A randomized trial of neoad juvant chemo-endocrine therapy in operable breast cancer. Proc Am Soc Clin Oncol ，1996，15:Abstr 51-56
5[5]Gazet JC, Coombes RC, Ford HT, et al . Assesssment of the effect o f pretreatment with neoadjuvant therapy on primary breast cancer.Br J Cancer,199 6，73:75-86
6[6]Dixon JM, Love CDB, Tucker S, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Proc ASCO, 1998, 17:104a
7[7]Harris L,Swain SM.The role of primary chemotherapy in early breast cancer.Semin Oncol， 1996，23:31-36
8Cserni G, et al. World J Surg 2000; 24(3):341-344.
9Baichev G, et al. Akush Ginekol Sofi ia 1999; 38(3): 41-43.
10Bobin JY, et al. Eur J Cancer 1999; 35 (4): 569-573.
1Jemal A, Bray F, Center MM, et al.Global cancer statistics [J]. CA Cancer J Clin,2011,61(2) :69-90.
2M ark opoulos C, Polychronis A, Zobolas V, et al.The effect of exemes- tane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub- study [J]. Breast Cancer Res Treat, 2005,93 ( l ) : 61-66.
3Simon 1t, Latreille J, Matte C, et al. Adherence to adjuvant endo- crine therapy in estrogen receptor-positive breast cancer patients with regular follow-up [ J ]. Can J Surg, 2014,57 ( 1) :26-32.
4Duffy JR, Hoskins LM, Chen MC, et al. Nonpharmacological strate- gies for improving heart failure outcomes in tile emmnunity: a sys- tematic review[ J ]. Nurs Care Qual, 2004,19(4):349-360.
5Chlebowski RT, Gel|er ML. Adherence to endocrine therapy tor breast cancer[J]. Oncolagy,2006,71 (1-2) : 1-9.
6Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-pnsitive tumors [J ]. J Natl Cancer Inst, 1996,88(21 ) : 1529-1542.
7Hutchins LF, Green SJ, Ravdin PM, et al. Randonfized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus ey- clophosphamide, doxorubiein, and fluorouraeil with and without tamoxifen for high-risk, node-negative breast eancer: treatment re- suits of intergroup protocol INT-0102 [J]. J Clin Oneol, 2005,23 (33) :8313-8321.
8Early breast cancer trialists collaborative group. Tamoxifen for ear- ly breast cancer. An overview of the randomized trials [J ].Lancet, 1993,51 (9114) : 1451-1467.
